MA34641B1 - Anticorps anti-il-23 - Google Patents
Anticorps anti-il-23Info
- Publication number
- MA34641B1 MA34641B1 MA35866A MA35866A MA34641B1 MA 34641 B1 MA34641 B1 MA 34641B1 MA 35866 A MA35866 A MA 35866A MA 35866 A MA35866 A MA 35866A MA 34641 B1 MA34641 B1 MA 34641B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- therapeutic
- methods
- well
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
Abstract
La présente invention concerne des composés anti-interleukine se liant à 23pl9, en particulier des anticorps anti-IL-23pl9 humanisés ainsi que des procédés et compositions thérapeutiques et de diagnostic permettant d'utiliser ces anticorps.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41015810P | 2010-11-04 | 2010-11-04 | |
US41195310P | 2010-11-10 | 2010-11-10 | |
US41259410P | 2010-11-11 | 2010-11-11 | |
US201161448785P | 2011-03-03 | 2011-03-03 | |
PCT/US2011/058869 WO2012061448A1 (fr) | 2010-11-04 | 2011-11-02 | Anticorps anti-il-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34641B1 true MA34641B1 (fr) | 2013-11-02 |
Family
ID=44936573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35866A MA34641B1 (fr) | 2010-11-04 | 2013-05-02 | Anticorps anti-il-23 |
Country Status (39)
Country | Link |
---|---|
US (5) | US8778346B2 (fr) |
EP (4) | EP3456740A1 (fr) |
JP (3) | JP6126532B2 (fr) |
KR (2) | KR101931591B1 (fr) |
CN (2) | CN103282382B (fr) |
AP (1) | AP3953A (fr) |
AR (1) | AR083747A1 (fr) |
AU (3) | AU2011323426B2 (fr) |
BR (1) | BR112013011065B1 (fr) |
CA (2) | CA2816950C (fr) |
CO (1) | CO6801628A2 (fr) |
CY (2) | CY1118014T1 (fr) |
DK (1) | DK2635601T3 (fr) |
EA (2) | EA201890548A1 (fr) |
EC (1) | ECSP13012649A (fr) |
ES (1) | ES2593754T3 (fr) |
GE (1) | GEP201706733B (fr) |
HK (1) | HK1247940A1 (fr) |
HR (1) | HRP20161141T1 (fr) |
HU (2) | HUE030916T2 (fr) |
IL (2) | IL225648A (fr) |
LT (2) | LT2635601T (fr) |
LU (1) | LUC00132I2 (fr) |
MA (1) | MA34641B1 (fr) |
ME (1) | ME02499B (fr) |
MX (3) | MX2019000046A (fr) |
MY (1) | MY162791A (fr) |
NL (1) | NL301013I2 (fr) |
NO (1) | NO2019038I1 (fr) |
NZ (1) | NZ610592A (fr) |
PE (1) | PE20141162A1 (fr) |
PL (1) | PL2635601T3 (fr) |
PT (1) | PT2635601T (fr) |
RS (1) | RS55161B1 (fr) |
SG (2) | SG190006A1 (fr) |
SI (1) | SI2635601T1 (fr) |
TW (2) | TWI653242B (fr) |
UY (1) | UY33703A (fr) |
WO (1) | WO2012061448A1 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
ES2593754T3 (es) * | 2010-11-04 | 2016-12-13 | Boehringer Ingelheim International Gmbh | Anticuerpos anti-IL-23 |
ES2908474T3 (es) * | 2012-05-03 | 2022-04-29 | Boehringer Ingelheim Int | Anticuerpos anti-IL-23p19 |
TWI636063B (zh) * | 2013-03-08 | 2018-09-21 | 美國禮來大藥廠 | 結合il-23之抗體 |
AP2015008801A0 (en) | 2013-03-15 | 2015-10-31 | Amgen Inc | Methods for treating crohn's disease using an anti-il23 antibody |
WO2014149425A1 (fr) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Méthodes de traitement du psoriasis à l'aide d'un anticorps anti-il-23 |
EP3708679A1 (fr) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarqueurs utiles dans le traitement de maladies liées à l'il-23a |
SG11201701423RA (en) * | 2014-09-03 | 2017-03-30 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
IL307578A (en) | 2015-02-04 | 2023-12-01 | Boehringer Ingelheim Int | Methods for treating inflammatory diseases |
CA2977534A1 (fr) | 2015-04-14 | 2016-10-20 | Boehringer Ingelheim International Gmbh | Methodes de traitement de maladies |
WO2017015433A2 (fr) | 2015-07-23 | 2017-01-26 | Boehringer Ingelheim International Gmbh | Composé ciblant le facteur d'activation d'il-23 et des lymphocytes b (baff) et utilisations associées |
WO2017049035A1 (fr) * | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prédiction de réponse clinique à des antagonistes d'il23 utilisant des biomarqueurs de la voie de l'il23 |
TWI811716B (zh) * | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
EP3371226A4 (fr) | 2015-11-03 | 2019-07-17 | Janssen Biotech, Inc. | Des anticorps se liant spécifiquement à pd -1 et le tim -3 et leurs utilisations |
JP2019508370A (ja) | 2015-12-22 | 2019-03-28 | アムジェン インコーポレイテッド | Il23アンタゴニストに対する臨床応答の予測因子としてのccl20 |
AU2017250583A1 (en) | 2016-04-15 | 2018-08-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
EP3848390A1 (fr) | 2016-10-14 | 2021-07-14 | Boehringer Ingelheim International GmbH | Procédés de traitement de maladies |
SG11202007420PA (en) * | 2018-02-05 | 2020-09-29 | Tesaro Inc | Pediatric niraparib formulations and pediatric treatment methods |
TWI744617B (zh) * | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
SG11202100185VA (en) | 2018-07-13 | 2021-02-25 | Astrazeneca Collaboration Ventures Llc | Treating ulcerative colitis with brazikumab |
CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
CN109810947B (zh) * | 2019-01-18 | 2021-06-11 | 北京贝来生物科技有限公司 | 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用 |
BR112021020612A2 (pt) * | 2019-04-15 | 2021-12-28 | Sun Pharmaceutical Ind Ltd | Métodos para tratamento de sujeitos com artrite psoriática |
WO2021126435A1 (fr) * | 2019-12-20 | 2021-06-24 | Novarock Biotherapeutics, Ltd. | Anticorps anti-interleukine-23 p19 et leurs méthodes d'utilisation |
CN111956606B (zh) * | 2020-08-31 | 2021-05-14 | 江苏荃信生物医药有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂 |
AR123477A1 (es) | 2020-09-10 | 2022-12-07 | Lilly Co Eli | Formulaciones de anticuerpos terapéuticos |
TW202231292A (zh) | 2020-10-13 | 2022-08-16 | 美商健生生物科技公司 | 用於調節分化簇iv及/或viii的經生物工程改造之t細胞介導之免疫力、材料、及其他方法 |
WO2022251623A1 (fr) | 2021-05-28 | 2022-12-01 | Eli Lilly And Company | Régulation d'anticorps anti-il-23p19 de gènes impliqués dans la rectocolite hémorragique |
KR20230009815A (ko) | 2021-07-09 | 2023-01-17 | 연세대학교 산학협력단 | Il-23에 의해 매개되는 질환의 중증도 예측용 조성물 |
EP4409298A1 (fr) | 2021-09-30 | 2024-08-07 | Eli Lilly and Company | Régulation d'anticorps anti-il-23p19 de gènes impliqués dans l'urgence intestinale dans la colite ulcéreuse |
WO2024077113A1 (fr) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Méthodes de traitement de la fatigue liée à la colite ulcéreuse |
WO2024085697A1 (fr) | 2022-10-21 | 2024-04-25 | Chong Kun Dang Pharmaceutical Corp. | Composition d'anticorps stable |
CN117875575B (zh) * | 2024-03-12 | 2024-05-28 | 中国电子科技集团公司第二十九研究所 | 一种基于混合仿生算法的干扰资源分配方法 |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
WO1981001145A1 (fr) | 1979-10-18 | 1981-04-30 | Univ Illinois | Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (fr) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Vecteurs de transformation de la levure yarrowia |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
EP0940468A1 (fr) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Domaine variable d'un anticorps humanisé |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
ES2112431T3 (es) | 1992-08-21 | 1998-04-01 | Genentech Inc | Procedimiento para el tratamiento de un trastorno mediado por lfa-1. |
RO118524B1 (ro) | 1992-11-13 | 2003-06-30 | Idec Pharmaceuticals Corp San | Metoda pentru tratarea unei tulburari legata de celulele b |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
WO1999040195A1 (fr) | 1998-02-06 | 1999-08-12 | Schering Corporation | Proteines de recepteurs de mammiferes; reactifs et procedes apparentes |
DE69942607D1 (de) | 1998-04-14 | 2010-09-02 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
HU230679B1 (en) | 1999-09-09 | 2017-08-28 | Merck Sharp & Dohme | Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
DK1287130T3 (da) | 2000-05-10 | 2008-09-01 | Schering Corp | Cytokinreceptorunderenhedproteiner fra pattedyr, tilhörende reagenser og fremgangsmåder |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
WO2003034818A1 (fr) | 2001-10-24 | 2003-05-01 | Chugai Seiyaku Kabushiki Kaisha | Animal non humain a srgf genetiquement modifie |
KR100913714B1 (ko) | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
EP2108660A1 (fr) | 2002-10-30 | 2009-10-14 | Genentech, Inc. | Inhibition de la production d'il-17 |
MXPA05006853A (es) | 2002-12-23 | 2005-08-16 | Schering Corp | Usos de citocinas de mamifero; reactivos relacionados. |
US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
MXPA05009717A (es) | 2003-03-10 | 2005-10-18 | Schering Corp | Usos de agonistas y antagonistas de interleucina-23; reactivos relacionados. |
US7413894B2 (en) | 2003-07-01 | 2008-08-19 | University Of Virginia Patent Foundation | TAG-1 and TAG-2 proteins and uses thereof |
EP1684805B8 (fr) | 2003-11-04 | 2010-08-25 | Novartis Vaccines and Diagnostics, Inc. | Utilisation d'anticorps monoclonaux antagonistes anti-cd40 pour le traitement de myelome multiple |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
JP5019881B2 (ja) | 2003-11-04 | 2012-09-05 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | アンタゴニスト抗cd40モノクローナル抗体およびそれらを使用するための方法 |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
JP4903061B2 (ja) | 2004-02-17 | 2012-03-21 | シェーリング コーポレイション | Il−23活性を調節する方法;関連する試薬 |
JP2007535930A (ja) | 2004-05-03 | 2007-12-13 | シェーリング コーポレイション | 皮膚の炎症を予測するためのil−17発現の使用;処置方法 |
US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
AU2005289594B2 (en) * | 2004-09-27 | 2012-02-02 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
TWI363091B (en) | 2004-12-20 | 2012-05-01 | Schering Corp | Uses of mammalian cytokine; related reagents |
PL2452694T3 (pl) | 2005-06-30 | 2019-06-28 | Janssen Biotech, Inc | Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania |
AU2006265898A1 (en) | 2005-06-30 | 2007-01-11 | Archemix Corp. | Polynucleotides and polypeptides of the IL-12 family of cytokines |
CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | 伊莱利利公司 | 抗il-23抗体 |
ES2347690T3 (es) * | 2005-08-25 | 2010-11-03 | Eli Lilly And Company | Anticuerpos anti-il-23. |
ME02705B (fr) | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Anticorps anti-il-23 obtenus par genie genetique |
ES2333260T3 (es) | 2005-09-01 | 2010-02-18 | Schering Corporation | Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica. |
WO2007076523A2 (fr) | 2005-12-28 | 2007-07-05 | Centocor, Inc. | Marqueurs et procedes permettant d'evaluer et de traiter le psoriasis et les troubles associes |
EP3219328B1 (fr) | 2005-12-29 | 2020-06-17 | Janssen Biotech, Inc. | Compositions, procédés et utilisations d'anticorps humains anti-il-23 |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
AU2007260787A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
BRPI0713133A2 (pt) | 2006-06-19 | 2012-03-27 | Wyeth Corp | métodos de modular il-22 e il-17 |
BRPI0806313A2 (pt) | 2007-01-09 | 2011-09-06 | Wyeth Corp | Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
CN101605532A (zh) | 2007-02-16 | 2009-12-16 | 惠氏公司 | 含有山梨糖醇的蛋白质调配物 |
ES2708988T3 (es) | 2007-02-23 | 2019-04-12 | Merck Sharp & Dohme | Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética |
CA2678863A1 (fr) | 2007-02-23 | 2008-08-28 | Schering Corporation | Anticorps obtenus par genie genetiques diriges contre l'il-23p19 |
US20100135998A1 (en) | 2007-02-28 | 2010-06-03 | Schering Corporation | Combination therapy for treatment of immune disorders |
CA2698357C (fr) | 2007-09-04 | 2017-06-06 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Deletions dans le domaine ii de l'exotoxine a de pseudomonas qui reduisent la toxicite non specifique |
AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
EP2212442A1 (fr) | 2007-10-26 | 2010-08-04 | Galderma Research & Development | Procédé non invasif pour études pharmaco-génomiques de maladies inflammatoires cutanées et leur procédé de diagnostic |
CA2607771A1 (fr) | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Anticorps recombinant humanise contre le virus de l'encephalite equine du venezuela |
CA2904458C (fr) | 2007-11-30 | 2017-07-25 | Wolfgang Fraunhofer | Formulations de proteine et leurs procedes de fabrication |
WO2009082624A2 (fr) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci |
MX2011001409A (es) | 2008-08-14 | 2011-03-29 | Cephalon Australia Pty Ltd | Anticuerpos anti-il-12/il-23. |
CA2734919C (fr) | 2008-08-27 | 2016-08-16 | Schering Corporation | Formulations lyophilisees d'anticorps anti-il-23p19 modifies |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
WO2010115786A1 (fr) | 2009-04-01 | 2010-10-14 | Glaxo Group Limited | Immunoglobulines anti-il-23 |
EP2414546A4 (fr) | 2009-04-02 | 2013-03-13 | Univ Johns Hopkins | Compositions et procédés pour le traitement ou la prévention des maladies intestinales inflammatoires chroniques et du cancer du colon |
WO2011011797A2 (fr) | 2009-07-24 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions de cytokine et leurs méthodes dutilisation |
WO2011066371A2 (fr) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Anticorps anti-il-6 et leur utilisation |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
CN102695465A (zh) | 2009-12-02 | 2012-09-26 | 斯帕泰克医疗股份有限公司 | 结合具有可偏转柱和复合脊柱杆的骨锚固件的小轮廓脊柱假体 |
GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
BR112012019881A2 (pt) | 2010-02-18 | 2017-06-27 | Bristol Myers Squibb Co | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 |
MX2012009755A (es) | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Composiciones que contienen anticuerpo estable. |
NZ602685A (en) | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
WO2011159750A1 (fr) | 2010-06-15 | 2011-12-22 | Celgene Corporation | Biomarqueurs pour le traitement du psoriasis |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
MX341309B (es) | 2010-07-20 | 2016-08-12 | Cephalon Australia Pty Ltd | Anticuerpos especificos del heterodimero de anti-il-23. |
EP2640745B1 (fr) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Anticorps bivalents et bispécifiques dirigés contre il-6 et il-23 |
ES2593754T3 (es) | 2010-11-04 | 2016-12-13 | Boehringer Ingelheim International Gmbh | Anticuerpos anti-IL-23 |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
TW201309330A (zh) | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
US9078894B2 (en) | 2011-02-04 | 2015-07-14 | Ab Science | Treatment of severe persistant asthma with masitinib |
ES2908474T3 (es) | 2012-05-03 | 2022-04-29 | Boehringer Ingelheim Int | Anticuerpos anti-IL-23p19 |
WO2014004436A2 (fr) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Anticorps il-23 anti-humains cristallins |
WO2014149425A1 (fr) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Méthodes de traitement du psoriasis à l'aide d'un anticorps anti-il-23 |
AP2015008801A0 (en) | 2013-03-15 | 2015-10-31 | Amgen Inc | Methods for treating crohn's disease using an anti-il23 antibody |
KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
SG11201701423RA (en) | 2014-09-03 | 2017-03-30 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
IL307578A (en) | 2015-02-04 | 2023-12-01 | Boehringer Ingelheim Int | Methods for treating inflammatory diseases |
WO2017015433A2 (fr) | 2015-07-23 | 2017-01-26 | Boehringer Ingelheim International Gmbh | Composé ciblant le facteur d'activation d'il-23 et des lymphocytes b (baff) et utilisations associées |
TWI811716B (zh) | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
-
2011
- 2011-11-02 ES ES11781949.0T patent/ES2593754T3/es active Active
- 2011-11-02 EA EA201890548A patent/EA201890548A1/ru unknown
- 2011-11-02 LT LTEP11781949.0T patent/LT2635601T/lt unknown
- 2011-11-02 MY MYPI2013001519A patent/MY162791A/en unknown
- 2011-11-02 WO PCT/US2011/058869 patent/WO2012061448A1/fr active Application Filing
- 2011-11-02 KR KR1020137011474A patent/KR101931591B1/ko active IP Right Grant
- 2011-11-02 CA CA2816950A patent/CA2816950C/fr active Active
- 2011-11-02 MX MX2019000046A patent/MX2019000046A/es unknown
- 2011-11-02 PL PL11781949T patent/PL2635601T3/pl unknown
- 2011-11-02 AU AU2011323426A patent/AU2011323426B2/en active Active
- 2011-11-02 SG SG2013031745A patent/SG190006A1/en unknown
- 2011-11-02 AP AP2013006820A patent/AP3953A/en active
- 2011-11-02 CN CN201180064083.5A patent/CN103282382B/zh active Active
- 2011-11-02 MX MX2013005015A patent/MX343858B/es active IP Right Grant
- 2011-11-02 SG SG10201604605VA patent/SG10201604605VA/en unknown
- 2011-11-02 RS RS20160762A patent/RS55161B1/sr unknown
- 2011-11-02 BR BR112013011065-1A patent/BR112013011065B1/pt active IP Right Grant
- 2011-11-02 JP JP2013537771A patent/JP6126532B2/ja active Active
- 2011-11-02 EP EP18188208.5A patent/EP3456740A1/fr not_active Withdrawn
- 2011-11-02 PE PE2013000951A patent/PE20141162A1/es active IP Right Grant
- 2011-11-02 PT PT117819490T patent/PT2635601T/pt unknown
- 2011-11-02 EA EA201300530A patent/EA030436B1/ru active Protection Beyond IP Right Term
- 2011-11-02 SI SI201130958A patent/SI2635601T1/sl unknown
- 2011-11-02 EP EP16178404.6A patent/EP3115375A1/fr not_active Withdrawn
- 2011-11-02 EP EP17179739.2A patent/EP3281954A1/fr not_active Withdrawn
- 2011-11-02 EP EP11781949.0A patent/EP2635601B1/fr active Active
- 2011-11-02 MX MX2016015419A patent/MX362039B/es unknown
- 2011-11-02 KR KR1020187036509A patent/KR102049223B1/ko active IP Right Grant
- 2011-11-02 CA CA3017116A patent/CA3017116A1/fr not_active Abandoned
- 2011-11-02 GE GEAP201113106A patent/GEP201706733B/en unknown
- 2011-11-02 CN CN201710917166.3A patent/CN107522784B/zh active Active
- 2011-11-02 DK DK11781949.0T patent/DK2635601T3/en active
- 2011-11-02 HU HUE11781949A patent/HUE030916T2/en unknown
- 2011-11-02 NZ NZ610592A patent/NZ610592A/en unknown
- 2011-11-02 US US13/287,208 patent/US8778346B2/en active Active
- 2011-11-03 UY UY0001033703A patent/UY33703A/es active IP Right Grant
- 2011-11-03 TW TW105114183A patent/TWI653242B/zh active
- 2011-11-03 AR ARP110104094A patent/AR083747A1/es active IP Right Grant
- 2011-11-03 TW TW100140204A patent/TWI545133B/zh active
-
2012
- 2012-11-02 ME MEP-2016-176A patent/ME02499B/fr unknown
-
2013
- 2013-04-09 IL IL225648A patent/IL225648A/en active Protection Beyond IP Right Term
- 2013-05-02 MA MA35866A patent/MA34641B1/fr unknown
- 2013-05-24 CO CO13128280A patent/CO6801628A2/es active IP Right Grant
- 2013-05-30 EC ECSP13012649 patent/ECSP13012649A/es unknown
- 2013-11-20 HK HK18107343.9A patent/HK1247940A1/zh unknown
-
2014
- 2014-06-12 US US14/302,986 patent/US9441036B2/en active Active
-
2016
- 2016-02-29 IL IL244335A patent/IL244335A/en active Protection Beyond IP Right Term
- 2016-08-04 US US15/228,254 patent/US10202448B2/en active Active
- 2016-09-06 HR HRP20161141TT patent/HRP20161141T1/hr unknown
- 2016-09-13 CY CY20161100899T patent/CY1118014T1/el unknown
- 2016-12-16 AU AU2016273970A patent/AU2016273970B2/en active Active
-
2017
- 2017-01-13 JP JP2017003955A patent/JP6445596B2/ja active Active
-
2018
- 2018-09-24 AU AU2018236692A patent/AU2018236692C1/en active Active
- 2018-11-29 JP JP2018223469A patent/JP6758361B2/ja active Active
-
2019
- 2019-01-25 US US16/257,463 patent/US20190144534A1/en not_active Abandoned
- 2019-10-14 LU LU00132C patent/LUC00132I2/fr unknown
- 2019-10-14 HU HUS1900048 patent/HUS1900048I1/hu unknown
- 2019-10-15 LT LTPA2019518C patent/LTC2635601I2/lt unknown
- 2019-10-16 NL NL301013C patent/NL301013I2/nl unknown
- 2019-10-17 NO NO2019038C patent/NO2019038I1/no unknown
- 2019-10-17 CY CY2019040C patent/CY2019040I1/el unknown
-
2020
- 2020-10-09 US US17/066,994 patent/US20210198355A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34641B1 (fr) | Anticorps anti-il-23 | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
MA33492B1 (fr) | Inhibiteurs de bace | |
MA34677B1 (fr) | Compositions pesticides et procedes apprentes | |
MA38248A1 (fr) | Compositions pesticides et procédés associés | |
MA34488B1 (fr) | Composition pesticides | |
MA34804B1 (fr) | Compositions pesticides et procedes apparentes | |
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
MX2018009945A (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
UA111818C2 (uk) | Антитіло проти csf-1r | |
EA200970581A1 (ru) | Кристаллическое твёрдое основание разагилина | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
MX2015005944A (es) | Cepas microbianas, composiciones y metodos para incrementar el fosfato disponible para las plantas. | |
MY155950A (en) | Anti-cd40 antibodies | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
BRPI0908926A2 (pt) | Compostos de policarbonato-poliorganosiloxano e/ou poliuretano-poliorganosiloxano | |
MA34598B1 (fr) | Procédés et compositions pour traiter le cancer du poumon | |
AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
MA33537B1 (fr) | Anticorps anti-cdcp1 humanisés | |
EA201200999A1 (ru) | Способы лечения рака молочной железы | |
EA201401193A1 (ru) | Триарильные соединения и композиции, их содержащие | |
MA35359B1 (fr) | Lutte biologique contre les nématodes |